Ergosterol isolated from the basidiomycete
*Pleurotus salmoneostramineus* affects
*Trypanosoma cruzi* plasma membrane and mitochondria

Tatiana Rodrigues Alexandre¹, Marta Lopes Lima¹,², Mariana Kolos Galuppo¹, Juliana Tonini Mesquita¹, Matília Ana do Nascimento¹, Augusto Leonardo dos Santos², Patricia Sartorelli³, Daniel Carvalho Pimenta⁴ and Andre Gustavo Tempone¹*

**Abstract**

**Background:** Major drawbacks of the available treatment against Chagas disease (American trypanosomiasis) include its toxicity and therapeutic inefficiency in the chronic phase of the infection, which makes it a concern among neglected diseases. Therefore, the discovery of alternative drugs for treating chronic Chagas disease requires immediate action. In this work, we evaluated the mushroom *Pleurotus salmoneostramineus* in the search for potential antiparasitic compounds.

**Methods:** Fruit bodies of the basidiomycete *Pleurotus salmoneostramineus* were triturated and submitted to organic solvent extraction. After liquid-liquid partition of the crude extract, three fractions were obtained and the bioguided fractionation study was conducted to isolate the active metabolites. The elucidation of the chemical structure was performed using GC-MS and NMR techniques. The biological assays for antiparasitic activity were carried out using trypomastigotes of *Trypanosoma cruzi* and murine macrophages for mammalian cytotoxicity. The mechanism of action of the isolated compound used different fluorescent probes to evaluate the plasma membrane permeability, the potential of the mitochondrial membrane and the intracellular levels of reactive oxygen species (ROS).

**Results:** The most abundant fraction showing the antiparasitic activity was isolated and chemically elucidated, confirming the presence of ergosterol. It showed anti-*Trypanosoma cruzi* activity against trypomastigotes, with an IC₅₀ value of 51.3 μg/mL. The compound demonstrated no cytotoxicity against mammalian cells to the maximal tested concentration of 200 μg/mL. The mechanism of action of ergosterol in *Trypanosoma cruzi* trypomastigotes resulted in permeabilization of the plasma membrane, as well as depolarization of mitochondrial membrane potential, leading to parasite death. Nevertheless, no increase in ROS levels could be observed, suggesting damages to plasma membrane rather than an induction of oxidative stress in the parasite.

**Conclusions:** The selection of naturally antiparasitic secondary metabolites in basidiomycetes, such as ergosterol, may provide potential scaffolds for drug design studies against neglected diseases.

**Keywords:** *Pleurotus salmoneostramineus*, Ergosterol, *Trypanosoma cruzi*, Mechanism of action

---

* Correspondence: atempone@usp.br
1 Center for Parasitology and Mycology, Instituto Adolfo Lutz, Avenida Dr. Arnaldo, 351, 8° andar, CEP 01246-000, São Paulo, SP, Brazil
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Chagas disease (CD) was described in 1909 by the Brazilian researcher Carlos Ribeiro Justiniano das Chagas [1]. It is currently estimated that 8 million people are infected worldwide, especially in 21 countries of Latin America. CD is responsible for 10,000 deaths annually, being a risk for 100 million people [2]. In Brazil, prevalent chronic cases of CD result from infections acquired in the past, affecting approximately three million individuals [2, 3]. However, in recent years, the occurrence of acute Chagas disease (ACD) has been observed in the Amazon, with the manifestation of isolated cases in other states [4]. Trypanosoma cruzi is the etiologic agent of CD, a hemoflagellate protozoan from the Kinetoplastida order [5]. Although CD has been described more than 100 years ago, the chemotherapy is, so far, limited to two nitro-heterocyclic drugs: benznidazole and nifurtimox [6]. Both are effective in the acute phase of the infection, with approximately 60–80% efficacy [7]. However, they are considered far from ideal in the chronic phase of the disease, with severe adverse effects and reduced efficacy [7, 8].

Due to this toxic and limited therapeutic arsenal, there is an urgent need to find new drugs. Considering that natural products have been providing interesting scaffolds for protozoan diseases, herein we investigated the potential of basidiomycetes, a rich source for antimicrobial compounds. For example, hypnofylline and panepoxidone isolated from the basidiomycete Lentinus strigosus and an ergosterol peroxide isolated from Pleurotus ostreatus have demonstrated anti-T. cruzi activities [9, 10]. Considering the genus Pleurotus, a number of secondary metabolites have been isolated with different biological properties, such as antitumor, antileishmanial, antimicrobial, anti-inflammatory and antitrypanosomal activities among others [9–14].

To the best of our knowledge, this is the first study that identified the antiparasitic potential of Pleurotus salmoneostamineus – popularly known as the “pink mushroom” – that grows on leaves of senescent plants found in Japan, New Guinea and Siberia. It is a popular mushroom because of the colorful body, flavor and texture, being rich in proteins, lipids, fiber, carbohydrates, vitamins and essential amino acids. It is generally used in reducing plasma cholesterol levels and prevents atherosclerosis [15, 16]. By using the bioguided fractionation, we isolated and chemically characterized the most abundant metabolite of P. salmoneostamineus with antitrypanosomal activity and evaluated its action on the plasma membrane, mitochondria and ROS levels of trypanastigotes forms of the parasite.

Methods

Basidiomycete and chemicals

The basidiomycete Pleurotus salmoneostamineus was commercially purchased from Zucca Funzionale (Brazil) and its identification was confirmed by the Adolfo Lutz Institute. Phosphate-buffered saline (PBS), Roswell Park Memorial Institute Medium (RPMI 1640), Hank’s Balanced Salt Solution (HBSS), sodium azide, Triton X-100, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), miltefosine, benznidazole (2-nitroimidazole), and the solvents dimethyl sulfoxide (DMSO), methanol (MeOH), hexane, ethyl acetate (EtOAc), butanol and dichloromethane were purchased from Sigma. The TLC Siligel 60 F254 aluminum chromatoplates with fluorescence indicators and common silica were purchased from Merk. Resazurin, sodium dodecyl sulfate (SDS), Sytox Green dye, Mitotracker Red CM-H2XROS, H2DCF-DA and MTT were purchased from Molecular Probes” (Invitrogen).

Parasites, mammalian cells and experimental animals

Trypomastigotes of Trypanosoma cruzi (Y strain) were maintained in LLC-MK2 (ATCC CCL 7) cells using RPMI-1640 medium supplemented with 2% fetal bovine serum (FBS) at 37 °C in 5% CO2 humidified incubator. LLC-MK2 (ATCC) cells were maintained in RPMI-1640 medium without phenol red and supplemented with 10% SBF at the same conditions [17]. Peritoneal macrophages were collected from the peritoneal cavity of female BALB/c mice by washing with RPMI-1640 without phenol red, supplemented with 10% FBS. BALB/c mice were supplied by the animal breeding facility at the Adolfo Lutz Institute and maintained in sterilized cages under a controlled environment, receiving water and food ad libitum. Animal procedures were performed with the approval of the Research Ethics Commission (CEUA-IAL-Pasteur 01/2011), in agreement with the Guide for the Care and Use of Laboratory Animals from the National Academy of Sciences.

Crude extract and liquid-liquid partition

Fruit-bodies of mushrooms basidiomycete P. salmoneostamineus (1000 g) were triturated and extracted with 1.4 L MeOH:H2O solution (1:1 v/v). This solution was sonicated (10 min), filtered (Whatman filter) and evaporated at 40 °C resulting in the crude extract. Subsequently, the crude extract was resuspended in 400 mL of water and partitioned using growing polarity solvents to afford the three fractions, n-hexane (518.8 mg), EtOAc (3432.9 mg) and butanol (1923.2 mg). Then, these fractions were dried at 40 °C and stored at −20 °C until analysis.

Determination of 50% inhibitory concentration (IC50) against Trypanosoma cruzi

To determine the 50% inhibitory concentration (IC50) against free trypomastigotes of T. cruzi obtained from LLC-MK2 cultures, 1 × 106 parasites/well were seeded
on 96-well microplates. N-hexane, EtOAc and butanol fractions were dissolved in MeOH, serially diluted (two-fold) in RPMI-1640 medium and incubated with the parasites in a range concentration between 300 and 2.3 μg/mL (final volume 200 μL) for 24 h, 37 °C, 5% CO₂. At the same conditions, the isolated compound was dissolved in DMSO, serially diluted (two-fold) and added to the highest concentration of 150 μg/mL. Benznidazole was used as a standard drug in a range concentration between 100 and 0.78 μg/mL. The parasite viability was determined by resazurin assay (0.11 mg/mL in PBS, 20 h incubation) using the FilterMax F5 Multi-Mode Microplate Reader, Molecular Devices (Sunnyvale, CA, USA), at 570 nm [18]. DMSO was used to dissolve the compounds and was included in the microplate at 0.5% (v/v) to avoid toxicity. Internal controls were also performed with DMSO. Additionally, the lethal effect of the isolated compound was confirmed on trypomastigotes using classical light microscopy analysis [19].

To determine the IC₅₀ against intracellular amastigotes of T. cruzi, peritoneal macrophages were dispensed in 16-well chamber slide (NUNC, Thermo, USA) and maintained for 24 h in the same medium at 37 °C in a 5% CO₂ humidified incubator for attachment. Non adherent cells were removed by two-step washings with medium. After 24 h, these cells were infected with 1 × 10⁶ culture trypomastigotes forms for 4 h. Subsequently, infected cells were incubated with the ergosterol in a range concentration between 100 and 0.78 μg/mL (final volume 200 μL) for 48 h. Finally, the slides were fixed with methanol, stained with Giemsa, and observed in a light microscope. The parasite load was defined by counting 400 macrophages/well by evaluating the number of infected macrophages. Benznidazole was used as standard drug and was included in the microplate at 0.5% (v/v) to avoid toxicity. Internal controls were also performed with DMSO. Additionally, the lethal effect of the isolated compound was confirmed on trypomastigotes using classical light microscopy analysis [19].

Cytotoxicity against mammalian cells
To determine the 50% cytotoxic concentration (CC₅₀) of the isolated compound, it was previously dissolved in DMSO, serially diluted (two-fold) in RPMI-1640 medium-10% SBF at maximum concentration of 200 μg/mL and incubated with 6 × 10⁴ peritoneal macrophages seeded on 96-well microplates, final volume of 200 μL during 48 h, 37 °C 5% CO₂. Cell viability was determined by resazurin assay as above described. Same conditions were applied to determine the CC₅₀ of the standard drug benznidazole, which was tested in a range concentration between 200 and 1.56 μg/mL [21]. DMSO was used to dissolve the compounds and was included in the microplate at 0.5% (v/v) to avoid toxicity. Internal controls were also performed with DMSO.

Hemolytic activity
The hemolytic activity of the isolated ergosterol was evaluated in BALB/c erythrocytes [22]. A 3% suspension of mouse erythrocytes was incubated for 2 h with the isolated compound at 100 μg/mL in 96-well U-shape microplate at 25 °C and the supernatant was read at 550 nm in a spectrophotometer FilterMax F5 Multi-Mode Microplate Reader, Molecular Devices (USA). Ultra pure distilled water was used as a positive control (100% hemolysis) and phosphate-buffered saline (PBS) as a negative control (0% hemolysis). DMSO was also used at 0.5% as internal control.

Mechanism of action of ergosterol
As standard conditions, free trypomastigotes of T. cruzi obtained from LLC-MK2 cultures were washed twice and seeded on 2 × 10⁶/well in PBS to 96-well black polystyrene microplate. The isolated compound was tested at the IC₉₉ value (100 μg/mL) and incubation was performed at 37 °C, 5% CO₂. Fluorescence was monitored using FilterMax F5 Multi-Mode Microplate Reader, Molecular Devices (USA) at respective wavelengths. In all mechanism assays, the following internal controls were used in presence of respective dyes (Sytox Green, MitoTracker Red CM-H2XROS or H₂DCF-DA): the background fluorescence of the isolated compound at the respective wavelengths; the possible interference of DMSO; untreated (control) trypomastigotes; and medium without any cells. Samples were tested in
triplicate and at least three independent assays were performed.

**Evaluation of plasma membrane permeability**

Under standard conditions, trypomastigotes were incubated with 1 μM Sytox Green for 15 min at 37 °C, 5% CO2 in the dark [23]. Then, the isolated compound was added at 100 μg/mL and the fluorescence was monitored every 20 min during 80 min at excitation (λex) and emission (λem) wavelengths of 485 and 520 nm, respectively. The maximum membrane permeabilization was obtained with 0.5% Triton X-100, as a positive control.

**Evaluation of the mitochondrial membrane potential**

Under standard conditions, trypomastigotes were incubated with the isolated compound at 100 μg/mL during 60 min and then MitoTracker Red CM-H2XROS (500 nM) was added and incubated for 40 min in dark. The minimal mitochondrial membrane potential was obtained by treatment of trypomastigotes with 10 μM FCCP, a known mitochondrial uncoupler. Trypomastigotes were washed twice with PBS before fluorescence reading at λem = 540 nm and λex = 595 nm [21].

**Detection of reactive oxygen species (ROS)**

Intracellular ROS levels were measured using fluorescent probe H2DCF-DA. Under standard conditions, except by the use of HBSS solution instead of PBS, trypomastigotes were incubated with the isolated compound ergosterol at 100 μg/mL and sodium azide (10 mM) as a positive control in order to obtain high levels of ROS production during 60 min. Then, fluorescent probe H2DCF-DA was added (5 μM, 15 min) and the fluorescence intensity measured at λem = 485 nm and λex = 520 nm [23].

**Statistical analysis**

The IC50 and CC50 values were calculated using sigmoid dose-response curves in GraphPad Prism 5.0 software, and the 95% confidence intervals are included in parentheses. The ANOVA test was used for significance p value. The data obtained from the mechanism of action represent the mean and standard deviation (SD) of triplicate samples from at least two independent assays.

**Results**

**Bioguided fractionation and antitrypanosomal activity**

The three obtained fractions (n-hexane, EtOAc and butanol) were incubated with free trypanosomes during 24 h and the viability determined by the resazurin assay. All fractions demonstrated anti-trypomastigote activity against the parasite resulting in 100% of death at the highest concentration of 300 μg/mL. The n-hexane, EtOAc and butanol fractions showed IC50 values of 7.9 μg/mL, 28.0 μg/mL and 58.3 μg/mL, respectively (Table 1). The TLC analysis determined a good resolution for the mixture of n-hexane:EtOAc (1:1, v/v) (data not shown). Together, the analytical assays and the antitrypanosomal activity of n-hexane fraction guided the subsequent separations, yielding 17 new fractions, which were compiled into ten groups (CPS1-10) based on their chromatographic similarities. The antitrypanosomal activity was detected in a crystallized fraction [namely CPS-3(3)], which resulted in an IC50 value of 51.3 μg/mL (46.1–57.0) against the trypomastigotes (Table 1).

**Biological activity of ergosterol**

The viability of trypamastigotes of T. cruzi and mammalian cells treated with ergosterol was determined by resazurin and MTT assay after 48 h of incubation. Ergosterol showed a moderate anti-trypomastigote activity with IC50 = 51.3 μg/mL; benznidazole was used as standard drug and resulted in an IC50 = 4.4 μg/mL. Additionally, light microscopy analysis confirmed the lethal effect of ergosterol in trypomastigotes. Ergosterol was also tested against the intracellular amastigotes of T. cruzi, but demonstrated no activity. Ergosterol (and benznidazole) showed lack of toxicity to BALB/c peritoneal macrophages to the maximal tested concentration of 200 μg/mL (Table 1). The hemolytic activity of ergosterol was tested in mice erythrocytes, but the compound induced no significant hemolysis (7.03% ± 11.6) to the highest tested concentration (7.03% ± 11.6) to the untreated cells.

**Ergosterol structural elucidation**

The CPS-3(3) fraction was subjected to 1H and 13C RMN and GC-EI-MS analysis for structural elucidation. 13C RMN spectra reveals C28-sterol ergostane skeleton, including signals of six unsaturated carbons at δC 116.3-

| Table 1 Antitrypanosomal activity of ergosterol and cytotoxicity against mammalian cells |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Compound**                  | **IC50 (μg/mL)** | **95% CI**      | **IC50 (μg/mL)** | **95% CI**      | **CC50 (μg/mL)** | **95% CI**      | **Selectivity index** | **Hemolytic activity (SD)** |
| Ergosterol                   | 51.3 (46.0–57.0) | >100            | >200            | >3.9            | 7.03% (±11.6)   |
| Benznidazole                | 4.4 (3.7–5.1)   | 1.9 (1.2–2.3)   | >200            | >45.0           | nd              |

IC50: 50% effective concentration; CC50: 50% cytotoxic concentration; 95% CI: 95% confidence interval; SI: selectivity index calculated as (SI = CC50 mammalian cell/IC50 trypomastigotes); nd: not determined
141.4 corresponding to C-5 (δ_C 139.8); C-6 (δ_C 119.6), C-7 (δ_C 116.3), C-8 (δ_C 141.4), C22 (δ_C 135.6) and C23 (δ_C 131.9). Methyl carbons were observed in C-18 (δ_C 12.1), C-19 (δ_C 16.3), C-21 (δ_C 21.1) C-26 (δ_C 28.3), C-27 (δ_C 19.7) and C-28 (δ_C 17.6), whereas hydroxyl group was observed in C-3 (δ_C 70.5). 1H RMN corroborated sterol Δ5,7 structure by signals δ_H 5.58 (dd, J = 3.0; 5.5 Hz) and 5.38 (dd, J = 2.9; 5.4 Hz) diagnostic for olefin hydrogens H-6 and H-7, besides multiplet in δ_H 3.64 (H-3) indicate the presence of hydrogen linked to carbonylic carbon. Double bonds were observed at signal 5.20 (m) relative to H-22 and H-23. Still, signals at region δ_H 0.8 and 1.1 relative to methyl groups identified two singlet hydrogen in δ_H 0.95 (CH3-C-18) and 0.65 (CH3-C-19), and four duplets in δH 0.82 (CH3-27), 0.84 (CH3-26); 0.92 (CH3-28), 1.04 (CH3-21). The assignment of all the carbon signals was performed by comparison with the reported data (Table 2). Table 1 compiles 1H and 13C RMN comparing with literature [24, 25].

GC-EI-MS also confirmed the identity and purity of ergosterol (Fig. 1) by the presence of m/z 396 corresponding to molecular formula C28H44O and fragments m/z 378 [M–H2O]+, m/z 363 [M–CH3-H2O]+, m/z 253 [M–side chain-H2O]+ and m/z 271 [M–side chain]+, a typical fragmentation profile of sterols [26] (Additional file 1).

Permeabilization of plasma membrane

Ergosterol (at IC<sub>99</sub> 100 μg/mL) was incubated for 80 min with trypomastigotes and the permeability of plasma membrane was evaluated through the fluorescence of Sytox Green dye (1 μM). The entrance of Sytox

Table 2 13C and 1H RMN data for ergosterol (75 MHz and 300 MHz)

| Position | δ_C EXP | δ_C LIT.a | δ_H EXP | δ_H LIT.b |
|----------|---------|-----------|---------|-----------|
| 1        | 38.4    | 38.5      |         |           |
| 2        | 31.9    | 32.1      |         |           |
| 3        | 70.5    | 70.5      | 3.64 m (1H) | 3.61 m (1H) |
| 4        | 40.8    | 40.9      |         |           |
| 5        | 139.8   | 139.8     |         |           |
| 6        | 119.6   | 119.7     | 5.58 dd (5.5, 3.0 Hz, 1H) | 5.56 dd (5.4, 2.2 Hz, 1H) |
| 7        | 116.3   | 116.4     | 5.38 dd (5.4, 2.9 Hz, 1H) | 5.38 dd (5.4, 2.5 Hz, 1H) |
| 8        | 141.4   | 141.3     |         |           |
| 9        | 46.2    | 42.3      |         |           |
| 10       | 37.1    | 37.1      |         |           |
| 11       | 21.1    | 21.1      |         |           |
| 12       | 39.1    | 39.1      |         |           |
| 13       | 42.9    | 42.9      |         |           |
| 14       | 54.6    | 54.6      |         |           |
| 15       | 22.9    | 23.1      |         |           |
| 16       | 28.3    | 28.3      |         |           |
| 17       | 55.7    | 55.8      |         |           |
| 18       | 12.1    | 12.1      | 0.95 s (3H) | 0.95 s (3H) |
| 19       | 16.3    | 16.3      | 0.65 s (3H) | 0.63 s (3H) |
| 20       | 40.3    | 40.4      |         |           |
| 21       | 21.1    | 21.2      | 1.04 d (J = 6.6 Hz, 3H) | 1.00 d (J = 6.6 Hz, 3H) |
| 22       | 135.6   | 135.6     | 5.20 m (1H) | 5.20 m (1H) |
| 23       | 131.9   | 132.1     | 5.21 m (1H) | 5.20 m (1H) |
| 24       | 42.9    | 42.9      |         |           |
| 25       | 33.1    | 33.1      |         |           |
| 26       | 19.9    | 20.0      | 0.84 d (J = 6.7 Hz, 3H) | 0.84 d (J = 6.7 Hz, 3H) |
| 27       | 19.7    | 19.7      | 0.82 d (J = 6.7 Hz, 3H) | 0.83 d (J = 6.7 Hz, 3H) |
| 28       | 17.6    | 17.6      | 0.92 d (J = 6.6 Hz, 3H) | 0.95 d (3H) |

a [21]  
b [22]
Green dye is allowed solely in injured plasma membrane, otherwise, its influx is precluded and no fluorescence can be measured. The increase of the dye caused by ergosterol (Fig. 2) were significant ($p < 0.002$) compared to untreated parasites, suggesting the alteration of the plasma membrane permeability when compared to the positive control with 0.5% Tx100 ($p < 0.001$), a non-ionic detergent (Fig. 2).

Alteration of mitochondrial membrane potential
Alteration in mitochondrial membrane potential was determined by the fluorescence of Mitotracker Red CM-H$_2$XROS dye (500 nM) in trypomastigotes treated with ergosterol (100 μg/mL) for 60 min. Ergosterol treatment caused significant decreased in the accumulation of Mitotracker Red at mitochondria indicating an effect of depolarization since normal potential guided maximal accumulation of dye in untreated trypomastigotes (control). Mitochondrial dysfunction promoted by ergosterol was comparable to that achieved by the treatment with 10 μM FCCP (Fig. 3).

Reactive oxygen species (ROS) production
The production of ROS in trypomastigotes incubated with ergosterol (60 min, 100 μg/mL) was evaluated by the fluorescence of H$_2$DCF-DA dye (5 μM). Trypomastigotes treated with ergosterol showed no significant increase in the production of ROS, showing levels similar to the untreated parasites. Trypomastigotes treated with sodium azide (10 mM) showed intense fluorescence as a positive control (Fig. 4).

Discussion
Natural secondary metabolites isolated from basidiomycetes have been described as rich source of bioactive molecules. Terpenoids isolated from *Lentinus strigosus* and lanostane-type triterpenes isolated from *Astraeus hygrometricus* are some examples of compounds with
promising activity against protozoan parasites such as *T. cruzi* and *Leishmania* [9, 24, 27].

Few studies on the chemical composition of mushrooms *Pleurotus salmoneostramineus* have been performed whereas the evaluation of their biological activities remains underexplored [15, 28, 29]. In the present study, the fractionating of the organic crude extract of *P. salmoneostramineus* yielded an antitrypanosomal substance. Our initial data demonstrated the presence of antiparasitic compounds in fractions of different polarities, such as *n*-hexane, EtOAc and butanol, which suggests that no single compound exists with efficacy against *T. cruzi* parasites. Among them, the ergosterol was isolated in large amount as a crystalized pure substance further elucidated by NMR and GC-EI-MS based in the literature data [24–26].

Ergosterol is the major sterol that composes membranes of *T. cruzi* parasites – including plasma, inner mitochondrial and glycosomal membranes – instead of cholesterol, its counterpart in mammalian cells that is usually confined to the plasma membrane [30–32]. *Trypanosoma cruzi* normally synthesizes sterols and occasionally leucine from carbon precursors [33]. The singularity of the sterol composition of *T. cruzi* parasites – closest to fungi cells than to mammalian host cells – has validated SBP as target for new therapeutic drugs [34]. Indeed, *T. cruzi* CPY51 (*Tc*CPY51) inhibitors – posaconazole and ravuconazole – entered in Drugs for Neglected Diseases Initiative (DNDi) clinical trials for Chagas disease despite the clinical failure recently reported [35, 36]. In general, the efficacy of *Tc*CPY51 inhibitor has been considerably variable depending on the parasite strain and time of exposure [36, 37].

In addition to *Tc*CPY51 inhibitors, sterols isolated from different natural sources including plants, marine sponges and amphibians have demonstrated to present antiprotozoan activities. Interestingly, ergosterol itself can be trypanocidal at unusual levels from its natural metabolism [22, 38, 39]. For example, *T. cruzi* amastigotes had 94% of growth inhibited by 10 μM of ergosterol [40]. A previous study demonstrated that ergosterol peroxide, but not ergosterol, isolated from the basidiomycete *Pleurotus ostreatus* also presented anti-*T. cruzi* activity, with an IC₅₀ value of 6.7 μg/mL against the insect form, epimastigotes [10]. When compared to our results, the previous work suggests that ergosterol peroxide is approximately 8-fold more active than ergosterol against trypomastigote forms. This could be due to the presence of the endoperoxide group, a known structure presenting potential biological properties [41, 42].

Additionally, differences may rely on metabolic specificities among forms of *T. cruzi*. For example, extracellular epimastigotes found in the insect vector have been described to be more susceptible to drugs than trypomastigotes, a parasite form found inside cells and bloodstream of vertebrate hosts [43]. Relapse and therapeutic failure have been described to arise from resident trypomastigotes, usually not affected by conventional therapy, which preferentially target intracellular amastigotes [44]. This information highlight the importance of selecting new anti-trypomastigote compounds.

The lethal action of ergosterol against trypomastigotes of *T. cruzi* was investigated. Ergosterol-treated trypomastigotes showed a rapid plasma membrane permeabilization as determined by the Sytox Green fluorescence. Alterations in plasma membrane composition are known to
modify fluidity and cellular morphology. For example, high concentrations of ergosterol have been speculated to be associated with rigidity, whereas low concentrations cause disorganization/disruption of the plasma membrane [45–47]. In our work, the physicochemical properties of ergosterol may have contributed to its crossing through plasma membrane, thus rapidly altering the permeability by disturbing normal lipid composition and modifying its fluidity and permeability. Disturbances of plasma membrane permeability largely contribute to trypomastigote death. Numerous metabolites from natural origin including sulforaphane, dermaseptins and phylloleptin have been reported to trigger such death mechanism [20, 23]. Moreover, drugs in clinical use for leishmaniasis such as miltefosine and amphotericin B are known to alter the permeability of plasma membrane [48, 49]. In this study, *T. cruzi* trypomastigotes treated with ergosterol suffered a rapid depolarization of the mitochondrial membrane potential probably by a direct accumulation in the mitochondria or as a secondary effect of the disturbance in plasma membrane permeability. Corroborating the previous hypothesis, exogenous ergosterol, but not cholesterol, is capable of abolishing the ketoconazole-induced massive swelling of the mitochondria [50].

Under conditions of permeability disturbance and loss of mitochondrial potential, the single mitochondria of *T. cruzi* may produce excessive ROS [51–53]. Our results demonstrated that ergosterol-treated trypomastigotes did not present significant alteration in ROS levels. These data suggest that exogenous supplementation of ergosterol may target the mitochondria and act as ROS scavengers, as indicated by a recent finding reported elsewhere [46]. Additionally, *Leishmania* (*Leishmania*) *donovani* parasites that are CYP51-defective constitutively present low ergosterol levels and higher susceptibility to oxidative stress induced by antimony [54]. The cell viability is increased during exposure to antimony by in vitro supplementation of ergosterol [45]. Therefore, we suggest that oxidative stress may not be contribute to the mechanism of action of ergosterol in *T. cruzi* parasites.

Conclusion

The basidiomycete mushroom *Pleurotus salmoneos- mineus* demonstrated to be an interesting and underexplored natural source for antiparasitic metabolites. Disturbances in the permeability of plasma membrane and loss of mitochondrial membrane potential without involvement of oxidative stress were pointed as initial mechanisms of action of ergosterol against *T. cruzi*. Although ergosterol is a constituent of the plasma membrane of *T. cruzi*, it is also effective to eliminate the parasite. The compound is a low cytotoxic substance that may be useful as scaffold for future synthesis of new derivatives against *Trypanosoma cruzi*.

Additional file

**Additional file 1:** Ergosterol fragmentation proposal interpreted from GM-EI-MS analysis. (DOCX 31 kb)

Abbreviations

ACD: Acute Chagas disease; CC: Column chromatography; CC₅₀: 50% cytotoxic concentration; CD: Chagas disease; CPS: Column *Pleurotus salmoneosmineus*; DMSO: Dimethyl sulfoxide; DNDi: Drugs for Neglected Diseases Initiative; EtOAc: Ethyl acetate; FBS: Fetal bovine serum; HBSS: Hank’s Balanced Salt Solution; IC₅₀: 50% inhibitory concentration; PBS: Phosphate-buffered saline; ROS: Reactive oxygen species; RPMI: Roswell Park Memorial Institute Medium; SBP: Sterol biosynthetic pathway; SDS: Sodium dodecyl sulfate; TcCPY51: *T. cruzi* CPY51; TLC: Thin layer chromatography

Funding

This work was supported by grants from São Paulo State Research Foundation (FAPESP 2013/50228-8, 2016/24985-4) and scholarships from CAPES.

Availability of data and materials

All data generated or analyzed during this study are included in this article and its Additional file 1.

Authors’ contributions

TRA, JTM, MLL, MKG and MAN performed the research and analyzed data. DCP and PS performed NMR and GC-MS analysis. MLL, MKG and AGT wrote the manuscript. AGT and DCP designed the study. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Animal procedures were approved by the Research Ethics Commission of Adolfo Lutz Institute (CEUA-JAL-Pasteur 01/2011) and were in agreement with the Guide for the Care and Use of Laboratory Animals from the National Academy of Sciences.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Center for Parasitology and Mycology, Instituto Adolfo Lutz, Avenida Dr. Arnaldo, 351, 8th andar, CEP 01246-000, São Paulo, SP, Brazil. 2. Institute of Tropical Medicine of São Paulo, University of São Paulo (USP), São Paulo, SP, Brazil. 3. Institute of Environmental, Chemical and Pharmaceutical Sciences, Federal University of São Paulo, São Paulo (UNIFESP), Diadema, SP, Brazil. 4. Laboratory of Biochemistry and Biophysics, Butantan Institute, São Paulo, SP, Brazil.

Received: 3 February 2017 Accepted: 19 May 2017

Published online: 30 May 2017

References

1. Bestetti RB, Cardinalli-Neto A. Did death hinder the process of justice? Cafras Chagas and the Nobel Prize of 1935. Int J Cardiol. 2011;147(1):172–3.
2. WHO. World Health Organization. Chagas disease. http://www.who.int/ chagas/en/. Accessed 14 Jan 2017.
3. Pereira PCM, Navarro EC. Challenges and perspectives of Chagas disease: a review. J Venom Anim Toxins incl Trop Dis. 2013;19(1):34.
4. de Góes CE, Dos Santos SO, Sojo-Milano M, Amador EC, Tatté E, Souza DS, et al. Acute Chagas disease in the Brazilian Amazon: epidemiological and clinical features. Int J Cardiol. 2017;235:176–8.
5. De Souza W. Trypanosoma cruzi-host cell interaction. Front Immunol. 2014;5:339.

6. Boscardin SB, Torrechilas AC, Manarin R, Revelli S, Rey EG, Tonelli RR, et al. Chagas’ disease: an update on immune mechanisms and therapeutic strategies. J Cell Mol Med. 2010;14(6B):1373–84.

7. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiasis and leishmaniasis. Trends Parasitol. 2005;21(11):508–12.

8. Romana AJ, Castro SL, de Soeiro MN, Lannes-Vieira J, Ribiero I, Talvani A, et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz. 2010;105(2):233–8.

9. Souza-Fagundes EM, Cota BB, Trigos A, Romanha AJ, Corrêa-Oliveira R, et al. Isolation and characterization of a ergosterol peroxide from Pleurotus ostreatus. Phytother Res. 2012;26(6):938–43.

10. Ramos-Ligonio A, López-Monteon A, Trigos A. Trypanocidal activity of ergosterol peroxide from Pleurotus ostreatus. Braz J Med Biol Res. 2010;43(11):1054–61.

11. Ramos-Ligonio A, López-Monteon A, Trigos A. Trypanocidal activity of ergosterol peroxide from Pleurotus ostreatus. Phytother Res. 2012;26(6):938–43.

12. Boscardin SB, Torrechilas AC, Manarin R, Revelli S, Rey EG, Tonelli RR, et al. Chagas’ disease: an update on immune mechanisms and therapeutic strategies. J Cell Mol Med. 2010;14(6B):1373–84.

13. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiasis and leishmaniasis. Trends Parasitol. 2005;21(11):508–12.

14. Romana AJ, Castro SL, de Soeiro MN, Lannes-Vieira J, Ribiero I, Talvani A, et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz. 2010;105(2):233–8.

15. Usami A, Nakaya S, Nakahashi H, Miyazawa M. Chemical composition of antileishmanial activities of Basidiomycota fungi present in Atlantic rainforest in Brazil. Antonie Van Leeuwenhoek. 2009;95(3):227–32.

16. Wu X, Zheng S, Cui L, Wang H, Ng TB. Isolation and characterization of a salmoneostramineus from Pleurotus djamor. Mediators Inflamm. 2014;2014:805841.

17. Bettiol E, Samanovic M, Murkin AS, Raper J, Buckner F, Rodriguez A. Isolation and identification of antitrypanosomal and antimycobacterial active steroids from the sponge Lentinus strigosus. Braz J Microbiol. 2013;44(4):1059–65.

18. Mikus J, Steverding D. A simple colorimetric method to screen drug activity against intracellular Trypanosoma cruzi. Braz J Microbiol. 2003;34(6):129–42.

19. Simões-Silva MR, Nefertiti AS, De Araújo JS, Batista MM, Da Silva PB, Bahia MT, et al. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep. 2014;4:4703.

20. Planer JD, Hulverson MA, Arif JA, Ranade RM, Don R, Buckner FS. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl Trop Dis. 2014;8(7):e2977.

21. Prieto JM, Hulverman MA, Prieto JA, Randell AM, Don R, Buckner FS. Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. PLoS Negl Trop Dis. 2014;8(7):e2977.

22. Mercier AE, Maggs JL, Sun XM, Cohen GM, Chadwick J, O'Neill PM, et al. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem. 2007;282(13):9372–82.

23. Moseki S, Ramdev SK, Das RN, Lessler DJ, Lee KJ, et al. Endotrypanum monterogeii and EtT. djamor. Sci Pharm. 2011;79(1):137–44.

24. Velegiannakis P, Catterall J, Ooi JL, Clements C, Abbott G, Young L, et al. Cytotoxic, immunosuppressive, trypanocidal and antitumor activity on sarcoma 180. J Gen Appl Microbiol. 2010;56(3):231–9.

25. Bettoli E, Samanovic M, Murkin AS, Raper J, Buckner F, Rodriguez A. Identification of three classes of heterocaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl Trop Dis. 2009;3(2):e384.

26. Mikus J, Steverding D. A simple colorimetric method to screen drug activity against Leishmania using the dye Alamar Blue. Parasitol Res. 2000;94(3):227–32.

27. Chowdhury MMH, Kubra K, Ahmed SR. Screening of antimicrobial, antioxidant properties and bioactive compounds of some edible mushrooms cultivated in Bangladesh. Ann Clin Microbiol Antimicrob. 2015;14:8.

28. Lo YC, Lin SY, Ulziijargal E, Chen SY, Chien RC, Tzou YJ, et al. Comparative study of contents of several bioactive components in fruiting bodies and mycelia of culinary-medicinal mushrooms. Int J Med Mushrooms. 2012;14(1):27–36.

29. Rodrigues CD, Catisti R, Uyemura SA, Vercesi AE, Lira R, Rodrigues C, et al. The sterol composition of Trypanosoma cruzi changes after growth in different culture media and results in different sensitivity to digitoxin-permeabilization. J Eukaryot Microbiol. 2001;48(5):588–94.

30. Roberts CW, McLeod R, Rice DW, Chance ML, Goed LJ. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol Biochem Parasitol. 2003;126(2):129–42.

31. Usami A, Nakaya S, Nakahashi H, Miyazawa M. Chemical composition and aroma evaluation of volatile oils from edible mushrooms (Pleurotus salmoneostramineus and Pleurotus sajor-caju). J Oleo Sci. 2014;63(12):1323–32.

32. Wu X, Zheng S, Cui L, Wang H, Ng TB. Isolation and characterization of a novel ribonuclelease from the pink oyster mushroom Pleurotus djamor. J Gen Appl Microbiol. 2010;56(3):231–9.

33. Bettoli E, Samanovic M, Murkin AS, Raper J, Buckner F, Rodriguez A. Identification of three classes of heterocaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl Trop Dis. 2009;3(2):e384.

34. Moseki S, Ramdev SK, Das RN, Lessler DJ, Lee KJ, et al. Cytotoxic, immunosuppressive, trypanocidal and antileishmanial activities of Basidiomycota fungi present in Atlantic rainforest in Brazil. Antonie Van Leeuwenhoek. 2009;95(3):227–32.

35. Simões-Silva MR, Nefertiti AS, De Araújo JS, Batista MM, Da Silva PB, Bahia MT, et al. Phenotypic screening in vitro of novel aromatic amides against Trypanosoma cruzi. Antimicrob Agents Chemother. 2016;60(9):4701–7.

36. Moseki S, Ramdev SK, Das RN, Lessler DJ, Lee KJ, et al. Cytotoxic, immunosuppressive, trypanocidal and antileishmanial activities of Basidiomycota fungi present in Atlantic rainforest in Brazil. Antonie Van Leeuwenhoek. 2009;95(3):227–32.

37. Chowdhury MMH, Kubra K, Ahmed SR. Screening of antimicrobial, antioxidant properties and bioactive compounds of some edible mushrooms cultivated in Bangladesh. Ann Clin Microbiol Antimicrob. 2015;14:8.

38. Elsayed EA, El Emshey H, Wadaan MA, Azzr R. Mushrooms: a potential natural source of anti-inflammatory compounds for medical applications. Mediators Inflamm. 2014;2014:805841.

39. Usami A, Nakaya S, Nakahashi H, Miyazawa M. Chemical composition and aroma evaluation of volatile oils from edible mushrooms (Pleurotus salmoneostramineus and Pleurotus sajor-caju). J Oleo Sci. 2014;63(12):1323–32.

40. Wu X, Zheng S, Cui L, Wang H, Ng TB. Isolation and characterization of a novel ribonuclelease from the pink oyster mushroom Pleurotus djamor. J Gen Appl Microbiol. 2010;56(3):231–9.
47. Lazardi K, Urbina JA, de Souza W. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother. 1990;34(11):2097–105.

48. Brilhante RS, Caetano EP, Lima RA, Castelo Branco DS, Serpa R, Oliveira JS, et al. In vitro antifungal activity of miltefosine and levamisole: their impact on ergosterol biosynthesis and cell permeability of dimorphic fungi. J Appl Microbiol. 2015;119(4):962–9.

49. Yang TS, Ou KL, Peng PW, Liou BC, Wang WT, Huang YC, et al. Quantifying membrane permeability of amphotericin B ion channels in single living cells. Biochim Biophys Acta. 2013;1828(8):1794–801.

50. Urbina JA, Lazardi K, Aguirre T, Piras MM, Piras R. Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother. 1991;35(4):730–5.

51. Menna-Barreto RF, de Castro SL. The double-edged sword in pathogenic trypanosomatids: the pivotal role of mitochondria in oxidative stress and bioenergetics. Biomed Res Int. 2014;2014:Article ID 614014.

52. Lazarin-Bidóia D, Desoti VC, Ueda-Nakamura T, Dias Filho BP, Nakamura OV, Silva SO. Further evidence of the trypanocidal action of eupomatienoid-5: confirmation of involvement of reactive oxygen species and mitochondria owing to a reduction in trypanothione reductase activity. Free Radic Biol Med. 2013;60:17–28.

53. Santos MF, Harper PM, Williams DE, Mesquita JT, Pinto E, da Costa-Silva TA, et al. Anti-parasitic guanidine and pyrimidine alkaloids from the marine sponge Monanchora arbuscula. J Nat Prod. 2015;78(5):1101–12.

54. Verma S, Mehta A, Shaha C. CYP5122A1, a novel cytochrome P450 is essential for survival of Leishmania donovani. PLoS One. 2011;6(9):e25273.